Biosimilar use in medical oncology in Ireland: a missed opportunity to mitigate financial toxicity?
Saved in:
| Title: | Biosimilar use in medical oncology in Ireland: a missed opportunity to mitigate financial toxicity? |
|---|---|
| Authors: | Burton E; Pharmaceutical Care Research Group, School of Pharmacy, University College Cork, College Road, Cork, Ireland. edel.burton@ucc.ie.; School of Public Health, University College Cork, Cork, Ireland. edel.burton@ucc.ie.; Pharmacy Department, Bon Secours Hospital, Cork, Ireland. edel.burton@ucc.ie., Coakley KE; Department of Medical Oncology, Beaumount Hospital, Dublin, Ireland., Gaynor S; Patient and Public Involvement Contributor -Patient Consultative Committee, Cancer Trials Ireland, Dublin, Ireland., McDonagh M; Pharmaceutical Care Research Group, School of Pharmacy, University College Cork, College Road, Cork, Ireland., Palmer C; Pharmaceutical Care Research Group, School of Pharmacy, University College Cork, College Road, Cork, Ireland., Sahm LJ; Pharmaceutical Care Research Group, School of Pharmacy, University College Cork, College Road, Cork, Ireland.; Pharmacy Department, Mercy University Hospital, Cork, Ireland.; St. Patrick's Mental Health Services, Dublin, Ireland., O'Reilly S; Cancer Research @UCC, University College Cork, Cork, Ireland.; Department of Medical Oncology, Cork University Hospital, Wilton, Cork, Ireland. |
| Corporate Authors: | Biologics Impact on Patient Care and Treatment (Bio ImPAcT) Consortium |
| Source: | International journal of clinical pharmacy [Int J Clin Pharm] 2026 Jul 24. Date of Electronic Publication: 2026 Jul 24. |
| Publication Type: | Letter |
| Journal Info: | Publisher: Springer Country of Publication: Netherlands NLM ID: 101554912 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2210-7711 (Electronic) NLM ISO Abbreviation: Int J Clin Pharm Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
